Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy

Abstract

Sex steroids are known to modulate serum lipoproteins. Studies have suggested that serum testosterone levels are associated with a beneficial lipid profile. Androgen deprivation therapy (ADT) is employed in the treatment of recurrent and metastatic prostate cancer (PCa), resulting in profound hypogonadism. As male hypogonadism unfavorably influences lipid profile and men with PCa have high cardiovascular mortality, we evaluated the effects of long-term ADT on fasting lipids. This Cross-sectional study was conducted in a university-based research institution. We evaluated 44 men, 16 undergoing ADT for at least 12 months before the study (ADT group), 14 age-matched eugonadal men with non-metastatic PCa who were status post prostatectomy and/or radiotherapy and not on ADT (non-ADT group) and 14 age-matched eugonadal controls (Control group). None of the men had known history of diabetes or dyslipidemia. Mean age was similar in the three groups (P=0.37). Serum total (P<0.01) and free (P<0.01) testosterone levels were lower in the ADT group compared to the other groups. Men on ADT had higher body mass index (BMI) compared to the other groups (P<0.01). Men in the ADT group had significantly higher levels of total cholesterol compared to the other two groups (P=0.03). After adjustment for BMI, men on ADT continued to have significantly higher fasting levels of total cholesterol (P=0.02), LDL cholesterol (P=0.04) and non-HDL cholesterol (P=0.03) compared to the control group. No significant differences were seen in the levels of other lipoproteins between the three groups. These data show that men undergoing long-term ADT have higher total and LDL cholesterol than age-matched controls. Long-term prospective studies are needed to determine the time of onset of changes in these lipoproteins while on ADT and the influence of these changes on cardiovascular mortality.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Haffner SM, Mykkanen L, Valdez RA, Katz MS . Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77: 1610–1615.

    CAS  PubMed  Google Scholar 

  2. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH . Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 1997; 146: 609–617.

    Article  CAS  Google Scholar 

  3. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH . The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 3313–3318.

    Article  CAS  Google Scholar 

  4. Schleich F, Legros JJ . Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 2004; 151: 415–424.

    Article  CAS  Google Scholar 

  5. Basaria S, Lieb II J, Tang AM, DeWeese T, Carducci M, Eisenberger M et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxford) 2002; 56: 779–786.

    Article  CAS  Google Scholar 

  6. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261–4267.

    Article  CAS  Google Scholar 

  7. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599–603.

    Article  CAS  Google Scholar 

  8. Satariano WA, Ragland KE, Van Den Eeden SK . Cause of death in men diagnosed with prostate carcinoma. Cancer 1998; 83: 1180–1188.

    Article  CAS  Google Scholar 

  9. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C . Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (London) 2003; 104: 195–201.

    Article  CAS  Google Scholar 

  10. Henriksson P, Eriksson M, Ericsson S, Rudling M, Stege R, Berglund L et al. Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet 1989; 2: 1178–1180.

    Article  CAS  Google Scholar 

  11. Phillips GB, Pinkernell BH, Jing TY . The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14: 701–706.

    Article  CAS  Google Scholar 

  12. Lu-Yao G, Stukel TA, Yao SL . Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 2004; 171: 2285–2290.

    Article  Google Scholar 

  13. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261: 1165–1168.

    Article  CAS  Google Scholar 

  14. Friedl KE, Hannan Jr CJ, Jones RE, Plymate SR . High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 1990; 39: 69–74.

    Article  CAS  Google Scholar 

  15. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K . The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 657–660.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Braga-Basaria.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Braga-Basaria, M., Muller, D., Carducci, M. et al. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 18, 494–498 (2006). https://doi.org/10.1038/sj.ijir.3901471

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901471

Keywords

This article is cited by

Search

Quick links